Loading...

Aethlon Medical

BST:EJUN
Snowflake Description

Flawless balance sheet with limited growth.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
EJUN
BST
$6M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The last earnings update was 124 days ago. More info.


Add to Portfolio Compare Print
  • Aethlon Medical has significant price volatility in the past 3 months.
EJUN Share Price and Events
7 Day Returns
-8.9%
BST:EJUN
1.8%
DE Medical Equipment
-3.6%
DE Market
1 Year Returns
-73.2%
BST:EJUN
11.3%
DE Medical Equipment
-11.8%
DE Market
EJUN Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
Aethlon Medical (EJUN) -8.9% -26.7% -66.5% -73.2% - -
DE Medical Equipment 1.8% 1.2% 3% 11.3% 110.1% 241.7%
DE Market -3.6% -2.1% -0.8% -11.8% 12% 5.8%
1 Year Return vs Industry and Market
  • EJUN underperformed the Medical Equipment industry which returned 11.3% over the past year.
  • EJUN underperformed the Market in Germany which returned -11.8% over the past year.
Price Volatility
EJUN
Industry
5yr Volatility vs Market

Value

 Is Aethlon Medical undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
  • It is not possible to calculate the future cash flow value for Aethlon Medical. This is due to cash flow or dividend data being unavailable. The share price is €0.2863.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for Aethlon Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are Aethlon Medical's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
BST:EJUN PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-12-31) in USD $-0.34
NasdaqCM:AEMD Share Price ** NasdaqCM (2019-06-14) in USD $0.33
Germany Medical Equipment Industry PE Ratio Median Figure of 9 Publicly-Listed Medical Equipment Companies 34.78x
Germany Market PE Ratio Median Figure of 424 Publicly-Listed Companies 19.7x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of Aethlon Medical.

BST:EJUN PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= NasdaqCM:AEMD Share Price ÷ EPS (both in USD)

= 0.33 ÷ -0.34

-0.99x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aethlon Medical is loss making, we can't compare its value to the DE Medical Equipment industry average.
  • Aethlon Medical is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does Aethlon Medical's expected growth come at a high price?
Raw Data
BST:EJUN PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -0.99x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
-6.1%per year
Germany Medical Equipment Industry PEG Ratio Median Figure of 6 Publicly-Listed Medical Equipment Companies 2.91x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.47x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for Aethlon Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on Aethlon Medical's assets?
Raw Data
BST:EJUN PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-12-31) in USD $0.18
NasdaqCM:AEMD Share Price * NasdaqCM (2019-06-14) in USD $0.33
Germany Medical Equipment Industry PB Ratio Median Figure of 13 Publicly-Listed Medical Equipment Companies 4.18x
Germany Market PB Ratio Median Figure of 576 Publicly-Listed Companies 1.76x
BST:EJUN PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= NasdaqCM:AEMD Share Price ÷ Book Value per Share (both in USD)

= 0.33 ÷ 0.18

1.86x

* Primary Listing of Aethlon Medical.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Aethlon Medical is good value based on assets compared to the DE Medical Equipment industry average.
X
Value checks
We assess Aethlon Medical's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check)
  5. Aethlon Medical has a total score of 1/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is Aethlon Medical expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
-6.1%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is Aethlon Medical expected to grow at an attractive rate?
  • Unable to compare Aethlon Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
  • Unable to compare Aethlon Medical's earnings growth to the Germany market average as it is expected to be loss making during the next 1-3 years.
  • Aethlon Medical's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
BST:EJUN Future Growth Rates Data Sources
Data Point Source Value (per year)
BST:EJUN Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts -6.1%
BST:EJUN Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 123.2%
Germany Medical Equipment Industry Earnings Growth Rate Market Cap Weighted Average 12.4%
Germany Medical Equipment Industry Revenue Growth Rate Market Cap Weighted Average 6.2%
Germany Market Earnings Growth Rate Market Cap Weighted Average 12.7%
Germany Market Revenue Growth Rate Market Cap Weighted Average 5%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
BST:EJUN Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in USD Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
BST:EJUN Future Estimates Data
Date (Data in USD Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2020-03-31 1 -6 2
2019-03-31 0 -6 2
BST:EJUN Past Financials Data
Date (Data in USD Millions) Revenue Cash Flow Net Income *
2018-12-31 0 -4 -6
2018-09-30 0 -4 -5
2018-06-30 0 -4 -5
2018-03-31 0 -4 -6
2017-12-31 0 -4 -6
2017-09-30 0 -4 -6
2017-06-30 0 -4 -7
2017-03-31 0 -4 -7
2016-12-31 1 -4 -7
2016-09-30 1 -4 -7
2016-06-30 1 -4 -6
2016-03-31 1 -4 -5

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Aethlon Medical is not considered high growth as it is expected to be loss making for the next 1-3 years.
  • Aethlon Medical's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
BST:EJUN Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (5 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from Aethlon Medical Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:EJUN Future Estimates Data
Date (Data in USD Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2020-03-31 -0.27 -0.23 -0.30 2.00
2019-03-31 -0.34 -0.33 -0.34 2.00
BST:EJUN Past Financials Data
Date (Data in USD Millions) EPS *
2018-12-31 -0.34
2018-09-30 -0.30
2018-06-30 -0.34
2018-03-31 -0.46
2017-12-31 -0.60
2017-09-30 -0.72
2017-06-30 -0.87
2017-03-31 -0.94
2016-12-31 -0.88
2016-09-30 -0.89
2016-06-30 -0.76
2016-03-31 -0.66

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if Aethlon Medical will efficiently use shareholders’ funds in the future without estimates of Return on Equity.
X
Future performance checks
We assess Aethlon Medical's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
Aethlon Medical has a total score of 2/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has Aethlon Medical performed over the past 5 years?

The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare Aethlon Medical's growth in the last year to its industry (Medical Equipment).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • Aethlon Medical does not make a profit even though their year on year earnings growth rate was positive over the past 5 years.
  • Unable to compare Aethlon Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare Aethlon Medical's 1-year growth to the DE Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
Aethlon Medical's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from Aethlon Medical Company Filings, last reported 5 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

BST:EJUN Past Revenue, Cash Flow and Net Income Data
Date (Data in USD Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-12-31 0.22 -5.87 5.90
2018-09-30 0.30 -5.07 5.18
2018-06-30 0.30 -4.98 5.07
2018-03-31 0.15 -5.68 4.98
2017-12-31 0.07 -6.05 5.14
2017-09-30 0.00 -6.04 5.14
2017-06-30 0.39 -6.99 6.51
2017-03-31 0.39 -7.28 6.49
2016-12-31 0.60 -6.84 6.28
2016-09-30 0.90 -6.85 6.43
2016-06-30 0.70 -5.82 5.13
2016-03-31 0.89 -4.87 5.27
2015-12-31 0.88 -4.51 5.31
2015-09-30 0.61 -4.70 5.05
2015-06-30 0.90 -4.32 4.81
2015-03-31 0.76 -6.80 4.76
2014-12-31 1.27 -13.38 4.94
2014-09-30 1.31 -14.21 5.13
2014-06-30 1.48 -16.71 4.92
2014-03-31 1.62 -13.36 4.68
2013-12-31 1.32 -8.65 4.41
2013-09-30 1.45 -6.11 4.25
2013-06-30 1.21 -4.18 4.68
2013-03-31 1.23 -4.89 4.81
2012-12-31 1.23 -6.62 4.81
2012-09-30 1.98 -7.51 4.97
2012-06-30 1.58 -6.54 4.55

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if Aethlon Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if Aethlon Medical has efficiently used its assets last year compared to the DE Medical Equipment industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if Aethlon Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess Aethlon Medical's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
Aethlon Medical has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is Aethlon Medical's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up Aethlon Medical's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • Aethlon Medical is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • Aethlon Medical has no long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of Aethlon Medical's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • Low level of unsold assets.
  • Debt is covered by short term assets, assets are 5.2x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from Aethlon Medical Company Filings, last reported 5 months ago.

BST:EJUN Past Debt and Equity Data
Date (Data in USD Millions) Total Equity Total Debt Cash & Short Term Investments
2018-12-31 3.17 0.93 4.82
2018-09-30 4.01 0.90 5.08
2018-06-30 5.11 0.87 6.12
2018-03-31 6.03 0.84 6.97
2017-12-31 4.60 0.81 5.61
2017-09-30 0.02 0.78 0.92
2017-06-30 -0.95 1.05 0.33
2017-03-31 0.60 0.52 1.56
2016-12-31 0.00 0.41 0.63
2016-09-30 -0.13 0.61 0.56
2016-06-30 0.38 0.62 1.29
2016-03-31 1.50 0.50 2.12
2015-12-31 2.71 0.43 3.25
2015-09-30 3.88 0.34 4.21
2015-06-30 5.08 0.25 5.65
2015-03-31 0.65 0.16 0.86
2014-12-31 1.29 0.29 2.78
2014-09-30 -3.29 1.66 0.53
2014-06-30 -3.52 1.87 0.81
2014-03-31 -14.73 2.53 1.25
2013-12-31 -10.54 2.63 1.85
2013-09-30 -11.55 2.83 0.01
2013-06-30 -8.82 2.50 0.03
2013-03-31 -9.14 2.69 0.13
2012-12-31 -7.32 2.76 0.11
2012-09-30 -8.47 2.84 0.27
2012-06-30 -8.39 3.37 0.60
  • Aethlon Medical's level of debt (29.4%) compared to net worth is satisfactory (less than 40%).
  • Aethlon Medical had negative shareholder equity 5 years ago, it is now positive therefore their debt level has improved.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • Aethlon Medical has sufficient cash runway for 1.2 years based on current free cash flow.
  • Aethlon Medical has sufficient cash runway for 1.2 years if free cash flow continues to reduce at historical rates of -7% each year.
X
Financial health checks
We assess Aethlon Medical's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. Aethlon Medical has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is Aethlon Medical's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from Aethlon Medical dividends.
If you bought €2,000 of Aethlon Medical shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate Aethlon Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate Aethlon Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
BST:EJUN Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Germany Medical Equipment Industry Average Dividend Yield Market Cap Weighted Average of 8 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 327 Stocks 3.2%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.9%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

BST:EJUN Future Dividends Estimate Data
Date (Data in $) Dividend per Share (annual) Avg. No. Analysts
2020-03-31
2019-03-31

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as Aethlon Medical has not reported any payouts.
  • Unable to verify if Aethlon Medical's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of Aethlon Medical's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as Aethlon Medical has not reported any payouts.
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess Aethlon Medical's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can Aethlon Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. Aethlon Medical has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of Aethlon Medical's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Timothy Rodell
AGE 67
TENURE AS CEO 0.5 years
CEO Bio

Dr. Timothy C. Rodell, Jr., M.D., FCCP has been Interim Chief Executive Officer at Aethlon Medical, Inc. since December 10, 2018 and has been its Director since December 2018. Dr. Rodell is a Managing Partner of MTR, Inc. Dr. Rodell is the Founder of Barofold, Inc. He served as the President and Chief Executive Officer of Globeimmune Inc. from June 2005 and April 2003 to November 2016. He served as Chief Technology Officer of Oxis International, Inc. from 2000 to October 2000. He served as President of OXIS Therapeutics, Inc. from March 1998 to October 2000 and served as Chief Operating Officer of OXIS from March 1, 1996 to March 18, 1998. From 1999 to 2002, Dr. Rodell served as the President, Chief Executive Officer and Director at Endo Pharmaceuticals Colorado LLC (formerly RxKinetix, Inc). in Louisville, Colorado. Prior to joining OXIS, Dr. Rodell served as Executive Vice President for Operations and Product Development of Cortech, Inc., from 1985 to 1995, where he led all development of three clinical programs and co-led its successful IPO. He is Director of Globeimmune Inc. since April 2003. He served as a Director of Oxis International, Inc. since 2000. He is Board -certified in Internal Medicine and Pulmonary Medicine. He practiced and taught emergency medicine, internal medicine and pulmonary and critical care medicine at University of Colorado Health Sciences Center and Denver Health (formerly, Denver General Hospital). Dr. Rodell also served as a post-doctoral research fellow at Webb-Waring Lung Institute in Denver, Colorado. He is a Fellow of the American College of Chest Physicians. Dr. Rodell received his M.D. from University of North Carolina School of Medicine in 1980.

CEO Compensation
  • Insufficient data for Timothy to compare compensation growth.
  • Insufficient data for Timothy to establish whether their remuneration is reasonable compared to companies of similar size in Germany.
Management Team Tenure

Average tenure and age of the Aethlon Medical management team in years:

4.6
Average Tenure
64
Average Age
  • The tenure for the Aethlon Medical management team is about average.
Management Team

Jim Frakes

TITLE
CFO, Senior VP of Finance & Secretary
COMPENSATION
$254K
AGE
61
TENURE
8.8 yrs

Jim Joyce

TITLE
Consultant
COMPENSATION
$617K
AGE
56
TENURE
0.5 yrs

Timothy Rodell

TITLE
Interim CEO & Director
AGE
67
TENURE
0.5 yrs

Sunil Sawhney

TITLE
Head of Clinical Studies
TENURE
14.3 yrs

Richard Tullis

TITLE
Consultant
AGE
73
Board of Directors Tenure

Average tenure and age of the Aethlon Medical board of directors in years:

3.8
Average Tenure
69
Average Age
  • The tenure for the Aethlon Medical board of directors is about average.
Board of Directors

Chuck Fisher

TITLE
Chairman & Member of extracorporeal Therapy Advisory Board
COMPENSATION
$95K
AGE
71
TENURE
1.6 yrs

Timothy Rodell

TITLE
Interim CEO & Director
AGE
67
TENURE
0.5 yrs

Ed Broenniman

TITLE
Director
COMPENSATION
$77K
AGE
82
TENURE
20.3 yrs

Chetan Shah

TITLE
Director
COMPENSATION
$76K
AGE
49
TENURE
6 yrs

Nathan Levin

TITLE
Member of Extracorporeal Therapy Advisory Board

Claudio Ronco

TITLE
Member of Extracorporeal Therapy Advisory Board

Larry Cowgill

TITLE
Member of Sepsis & Inflammation Advisory Board

Greg Kovacs

TITLE
Member of Extracorporeal Therapy Advisory Board

John Kellum

TITLE
Member of Extracorporeal Therapy Advisory Board

David Ward

TITLE
Member of Extracorporeal Therapy Advisory Board
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess Aethlon Medical's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. Aethlon Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Company Info

Description

Aethlon Medical, Inc., a medical device company, focuses on creating devices that address unmet medical needs in health and biodefense worldwide. The company is developing Aethlon Hemopurifier, a clinical-stage therapeutic device that eliminates life-threatening viruses from the circulatory system of infected individuals. It is also involved in the development of exosomal biomarkers to diagnose and monitor life-threatening disease conditions, such as cancer and neurological disorders; and a therapeutic device to reduce the incidence of sepsis, a fatal bloodstream infection. The company was founded in 1991 and is based in San Diego, California.

Details
Name: Aethlon Medical, Inc.
EJUN
Exchange: BST
Founded: 1991
$5,577,272
18,960,505
Website: http://www.aethlonmedical.com
Address: Aethlon Medical, Inc.
9365 Granite Ridge Drive,
Suite 100,
San Diego,
California, 92123,
United States
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
NasdaqCM AEMD Common Stock Nasdaq Capital Market US USD 11. Mar 1999
BST EJUN Common Stock Boerse-Stuttgart DE EUR 11. Mar 1999
Number of employees
Current staff
Staff numbers
6
Aethlon Medical employees.
Industry
Health Care Equipment
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/06/15 22:02
End of day share price update: 2019/06/14 00:00
Last estimates confirmation: 2019/02/14
Last earnings filing: 2019/02/11
Last earnings reported: 2018/12/31
Last annual earnings reported: 2018/03/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.